OmniAb price target lowered to $4 from $7 at RBC Capital
RBC Capital lowered the firm’s price target on OmniAb (OABI) to $4 from $7 and keeps an Outperform rating on the shares. The company provided ...
Bausch + Lomb price reaction to recall ‘likely overdone,’ says RBC Capital
After Bausch + Lomb (BLCO) announced a voluntary recall of its enVista intraocular lenses, RBC Capital says talks with management indicated ...
4DMT to Participate in Upcoming Investor Conferences
D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...